Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,075

Document Document Title
WO/2019/136531A1
Disclosed are proteinaceous molecules corresponding to an acetylation site and their use for inhibiting or reducing the nuclear localization of a nuclear localizable polypeptide, such as PD-1, PD-L1 and PD-L2. This invention also relates...  
WO/2019/094938A3
The methods and compositions described herein address the need in the art by providing peptides and polypeptides comprising a growth factor binding domain. In some embodiments, the peptides have an amino acid sequence that is at least 80...  
WO/2019/126186A1
Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic p...  
WO/2019/096018A1
Provided herein are recombinant peptides useful for inhibiting the function of autophagy-related 8 (Atg8) proteins. The recombinant peptides can be used in the preparation of imaging agents for monitoring autophagy in a cell or subject a...  
WO/2019/094938A2
The methods and compositions described herein address the need in the art by providing peptides and polypeptides comprising a growth factor binding domain. In some embodiments, the peptides have an amino acid sequence that is at least 80...  
WO/2019/076856A1
The present invention relates to an adeno-associated virus (AAV), comprising an insertion of at least 6-8 amino acids between thepositions corresponding to position 87 and 588 of SEQ ID NO: 1. Also envisioned are AAVs of the present inve...  
WO/2019/074870A1
The present disclosure relates compositions and methods for combinatorial drug discovery in nanoliter droplets. More particularly, the disclosure relates to novel synergistic agents that increase efficacy of antibiotic agents to treat ba...  
WO/2019/055860A1
The invention relates to methods for treating cancers by targeting the elimination of selective activated immune cell populations in combination with checkpoint inhibitors. The cells may be targeted, for instance, using CLIP inhibitors a...  
WO/2019/039179A1
Provided is a means for conveniently isolating exosome from a sample containing exosome. The present invention relates to a method for isolating exosome, the method comprising: a complex formation step for binding a specific peptide cont...  
WO/2019/038789A1
The present disclosure provides a recombinant vector comprising BclB or BclA fused to a gene of interest encoding a fusion polypeptide for cell surface display of the fusion polypeptide. Also provided is a recombinant host cell comprisin...  
WO/2019/036761A1
A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may ...  
WO/2018/213320A1
Disclosed herein are conjugates including a fatty acid, a self-assembly domain, and a polypeptide having phase transition behavior. Further disclosed are methods of using the conjugates to treat disease, methods of delivering an agent, a...  
WO/2018/208606A1
Disclosed herein is a CAR construct encoding an inhibitor of immunodeficiency virus fusion and human CD4 extracellular and transmembrane domains linked to a human CD3ζ signaling domain, and methods of making and using thereof to treat, ...  
WO/2018/172065A1
The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing in...  
WO/2018/140974A1
Disclosed herein are methods, reagents, and pharmaceutical compositions for modulating immune effector cell activation that does not requirean antigen-specific antibody. The IgG Fc region is shown herein to contain both a domain that bin...  
WO/2018/132732A1
Disclosed herein are conjugates including a fatty acid, a self-assembly domain, and a polypeptide, where the conjugates have phase transition behavior. Further disclosed are methods of using the conjugates to treat disease, methods of de...  
WO/2018/130834A1
The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions.  
WO/2018/124425A1
The present invention relates to a novel peptide, a polynucleotide encoding the peptide, an expression vector comprising the polynucleotide, and a pharmaceutical composition, a quasi-drug composition, and a healthy functional food compos...  
WO/2018/115602A1
The present invention relates to therapeutic peptides.  
WO/2018/104922A1
The present invention relates to the efficient solid-phase synthesis of liraglutide represented by Formula-I. The present invention relates to an efficient process for the preparation of liraglutide by sequential coupling employing solid...  
WO/2018/106470A1
The present invention is drawn to compositions and methods for improving transformation frequency. The compositions, synthetic selectable marker genes, are used in transformation methods and result in increased transformation frequency.  
WO/2018/067291A1
Specifically, methods for patient stratification and selection of personalized peptide based treatments and vaccines are disclosed, including assays for identifying antigenic and immunogenic peptides involved in immune responses of mamma...  
WO/2018/048806A1
The present invention provides compounds that are antagonists of CXCR4 and methods for using the same for treatment of a clinical condition associated with CXCR4 activation. In particular, compounds of the invention include cyclic peptid...  
WO/2018/023028A1
Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with synucleinopathy and for measuring synucleinopathy progression or status. Test kits for diagnosis of an indiv...  
WO/2018/005556A1
Provided are methods of identifying peptide epitopes of an antigen recognized by the non-classical major histocompatibility complex (MHC) molecule designated MHC-E. In some embodiments, the antigen is a tumor antigen, autoimmune antigen ...  
WO/2017/219029A8
The invention provides compositions and methods useful for the depletion of CD1 17+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are ...  
WO/2017/219029A3
The invention provides compositions and methods useful for the depletion of CD1 17+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are ...  
WO/2017/190263A1
Provided are derivatives of a snake venom C fragment straight-chain polypeptide and a cyclic peptide related thereto, and a preparation method therefor. The derivatives comprise a parent peptide sequence as shown in formula I: R1-P1-Asp-...  
WO/2017/192460A1
This disclosure relates to isotopically modified amino acids and their pharmaceutical or nutritional uses in stabilizing pharmaceutical protein-based formulations, proteins with long life span, and preventing or treating disease such as ...  
WO/2017/188498A1
An antimicrobial peptide and an antimicrobial peptide composition containing the same, of the present invention, have remarkably higher antimicrobial activity against gram (+) and gram (-) strains than wild type LPcin-I, which has antimi...  
WO/2017/176076A1
The present invention relates to a novel, translationally controlled tumor protein derived-protein transduction domain (TCTP-PTD) having the ability to penetrate the cell membrane, and to the use thereof. The TCTP-PTD peptide of the pr...  
WO/2017/173321A1
The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.  
WO/2017/165617A1
Methods for assessing the efficacy of internally cross-linked p53 transactivation domain-based inhibitor peptides in the treatment of pediatric cancer and methods of using such peptides to treat pediatric cancer are provided.  
WO/2017/158367A1
The present invention relates to novel peptides derived from Progesterone-associated endometrial protein (PAEP), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC...  
WO/2017/150724A1
The present invention provides a novel soybean allergy antigen, a diagnostic method and diagnostic kit for soybean allergies, a pharmaceutical composition including the antigen, a soybean or soybean product in which the antigen has been ...  
WO/2017/115367A1
The present invention provides a composition and method for treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject. The composition a peptid...  
WO/2017/115853A1
A peptide having the following sequence is added as a peptide tag to a useful protein and expressed. Xm(PYn)qPZr Here, X, Y, and Z are amino acid residues each selected independently from R, G, S, K, T, L, N, Q, and H, and at l...  
WO/2017/100199A1
The present invention provides a method for treating a subject afflicted with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: a) admin...  
WO/2017/096036A1
The present disclosure is directed to HER2-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or...  
WO/2017/089778A1
The present invention relates to novel peptides derived from Homeobox protein Hox-B13 (HOXB13), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also ...  
WO/2017/089763A1
The present invention relates to novel peptides derived from DDB1 - and CUL4-associated factor 4- like protein 2 (DCAF4L2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in compl...  
WO/2017/089783A1
The present invention relates to novel peptides derived from Prostate specific antigen (KLK3), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also p...  
WO/2017/089773A1
The present invention relates to novel peptides derived from Structural maintenance of chromosomes protein 1 B (SMC1 B), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex ...  
WO/2017/089776A1
The present invention relates to novel peptides derived from Melanoma-associated antigen B2 (MAGEB2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules....  
WO/2017/089765A1
The present invention relates to novel peptides derived from Nuclear receptor subfamily 0 group B member 1 (NR0B1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with ...  
WO/2017/089774A1
The present invention relates to novel peptides derived from Melanoma-associated antigen C (MAGEC1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. ...  
WO/2017/089770A1
The present invention relates to novel peptides derived from melanoma-associated antigen C2 (MAGEC2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules....  
WO/2017/089775A1
The present invention relates to novel peptides derived from Immunoglobulin lambda-like polypeptide 1 (IGLL1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC m...  
WO/2017/089781A3
The present invention relates to novel peptides derived from Abnormal spindle-like microcephaly-associated protein (ASPM), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in comple...  
WO/2017/086090A1
The present invention provides a novel peptide having specific accumulation that acts directly on pancreatic cancer cells and tissues. The present invention is a peptide of (a) or (b) below. (a) A peptide comprising an amino acid sequenc...  

Matches 1 - 50 out of 1,075